Reorganization of the intravitreal therapy service with the use of a scoring system during Coronavirus disease 2019 pandemic in a tertiary referral center in Milan, Italy

With the recent Coronavirus disease (COVID-19) pandemic we have experienced a sudden and dramatic change of our scheduled work in every field of medicine, including ophthalmology (1-3).

Our Medical Retina (MR) service is usually overbooked because of the increasing demand of intravitreal treatments for exudative maculopathy (4,5). However with the ongoing pandemic and the restrictive measures adopted by our Government to limit the spread of the COVID-19 outbreak, only urgent cases have been allowed to attend the clinic during the pandemic peak. Therefore, we had to swiftly reorganise and reschedule the planned activity of our Service. The electronic medical records (EMR), clinical notes and retinal imaging of patients booked in our MR service were reviewed in order to assess the eligibility of patients to attend the Clinic.

Approximately thirty patients per day were phoned with the aim to assess their visual condition. Among the patients scheduled for the intravitreal therapies nearly half of them reported stability of vision. Of the remaining half who reported a drop of visual acuity, approximately half of them refused to come to the hospital because of the risk of COVID-19 infection. All the patients attending the clinic for intravitreal therapies were called at least once in a month during the peak of the pandemic (February–April 2020).

A scoring system (Table 1) based on demographic, clinical characteristics, and adherence to treatment of patients was applied for those patients already booked for intravitreal treatment. The priority of treatment was given to the patients with the highest score.

The score was computed by reviewing the retinal imaging and the clinical history on both EMR and clinical notes by two MR consultants (SE and MM).

In line with the recent guidelines and expert panel recommendations on anti-vascular endothelial growth factor (VEGF) treatment during COVID-19 pandemic (6,7), fixed dosing treatment was maintained for stable patients. For patients on treatment with a treat & extend regimen, the interval that provided a fluid-free macula was maintained.

Our approach led to a remarkable decrease of the number of examinations and therapies delivered per day by our MR service, especially during the peak of the pandemic. Between February and April 2020, we performed approximately half of the injections performed in the same period the year before (Figure 1).

Figure 1 Number of intravitreal injections performed in the period from January to April in 2019 (blue bar) and 2020 (red bar).

The decreased volume of visits and injections was aimed at avoiding the overcrowding of patients and carers in our clinic thus limiting contacts of patients, carers and health workers with possible sources of infection. However, this approach resulted in a certain delay of treatment in patients with a low score and therefore deemed to have lower priority than others.

Our approach has several limitations since we have not taken into account several factors such as the number of previous intravitreal injections, history of anti-VEGF switch and the lesions subtype. In our score we have given priority to young patients. Indeed, young age and myopic maculopathy, usually affecting patients younger than those with other exudative maculopathies, were given the highest points (Table 1). The reason of this choice is two-fold: blindness and low vision are increasing costs in our society and people in working age with eye disease could lead to early retirement, and social life limitations. Additionally, we sought to limit hospital visits in elderly people, who are at increased risk of complications and death following COVID-19 infection (8).

While we are aware of the limitations of our approach, COVID-19 pandemic was an unprecedented scenario that forced us to take tough decisions for a prompt reorganization of the clinic. We did not have the possibility to lean on proven strategies, since reliable guidelines came out after the pandemic peak in Italy (6,7,9).

In conclusion, our described approach, including the application of a scoring system for the patients eligible to the intravitreal therapy, helped us in the decision process about the priority of treatment among patients with exudative maculopathy during the COVID-19 pandemic peak in Italy. Follow-up of these patients is needed to clarify the effect of such approach in the long-term.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was a standard submission to the journal. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/aes-20-128). Dr. Casalino reports other from Hoffmann-La Roche, outside the submitted work and serves as an unpaid editorial board members of Annals of Eye Science from Sep 2020 to Aug 2022. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Yuan Y, Qiu T, Wang T, et al. The application of Temporary Ark Hospitals in controlling COVID-19 spread: The experiences of one Temporary Ark Hospital, Wuhan, China. J Med Virol 2020;82:2019-26. [Crossref] [PubMed]
2. Singer AJ, Morley EJ, Henry MC. Staying Ahead of the Wave. N Engl J Med 2020;382:e44 [Crossref] [PubMed]
3. Borrelli E, Sacconi R, Querques L, et al. Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy. Eye (Lond) 2020;34:1175-6. [Crossref] [PubMed]
4. Spooner KL, Mhlanga CT, Hong TH, et al. The burden of neovascular age-related macular degeneration: a patient's perspective. Clin Ophthalmol 2018;12:2483-91. [Crossref] [PubMed]
5. Wong TY, Sabanayagam C. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence. Ophthalmologica 2020;243:9-20. [Crossref] [PubMed]
6. Korobelnik JF, Loewenstein A, Eldem B, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020;258:1149-56. [Crossref] [PubMed]
7. Korobelnik JF, Loewenstein A. Vision Academy. Communicating with patients with nAMD and their families during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020;258:1335-7. [Crossref] [PubMed]
8. Giorgi Rossi P. Case fatality rate in patients with COVID-19 infection and its relationship with length of follow up. J Clin Virol 2020;128:104415 [Crossref] [PubMed]
9. Antaki F, Dirani A. Treating neovascular age-related macular degeneration in the era of COVID-19. Graefes Arch Clin Exp Ophthalmol 2020;258:1567-9. [Crossref] [PubMed]